Guardant Health price target lowered to $60 from $80 at BTIG

BTIG analyst Mark Massaro lowered the firm’s price target on Guardant Health to $60 from $80 and keeps a Buy rating on the shares. Guardant reported its highly anticipated ECLIPSE data, which came in at 83% sensitivity and 90% specificity, just below Street expectations, but Massaro regards it as strong data for FDA approval, Medicare reimbursement, and inclusion in the guidelines for the United States Preventive Services Task Force, the analyst tells investors in a research note.